Futura Medical Share Discussion Threads

[mike2042] 09/2/2024 15:14

Quick, quick MDI post more about how Eroxon is actually going to be a failure... *EVEN THOUGH EXROXON IS SELLING AND THE SAHRE PRICE IS GOING UP! (just look at todays intraday price activity)

[broomrigg] 09/2/2024 14:31

MDI/LBO bitter and broke 🤣🤣🤣🤣9315;🤣

[broomrigg] 09/2/2024 14:31

MDI then totally bottled it and sold all his shares sub 10p in 2018.....they have never gone that low again 🤣🤣🤣🤣9315;🤣

[takeiteasy] 09/2/2024 14:19

Yes an easy google search away so anyone here can do it :)

[mdi] 09/2/2024 14:17

‘publicly available web based government data on ED prescriptions sales’

‘ a comment about as relevant as the price of a mars bar in 1960...lols..’

www.chemistanddruggist.co.uk/CD005469/Viagra-Connect-sales-soar-following-pharmacy-launch

How is prescribing data relevant to Eroxon? Back in 2018 when Viagra connect alone launched in just 12 weeks:

‘According to research by market analysts IRI, sales of the erectile dysfunction drug reached £4.3 million in the 12 weeks after the product – Viagra Connect – became available to purchase over the counter (OTC) in pharmacies across the UK’

[2 solaris] 09/2/2024 14:15

This is a gem, a hidden one at the moment. The RNS gets more and more positive the more I read it!

Significant progress made in key target markets

FDA approval for Eroxon in the US, the largest market for ED in the world

Haleon plc secured as distribution partner for the US and $4 million upfront payment received which will be recognised in FY24

Successful launches in UK and Belgium through Cooper Consumer Health ("Cooper"), and extension of licencing agreement to 2029

Granted allowance of EU patent which will provide protection for Eroxon until 2040 in all European markets.

Proven demand for Eroxon - early data shows >20% market share in the UK and Belgium

Generation of first meaningful revenues and strong cash position

'Futura's European distribution partner, Cooper, launched in the UK and Belgium in March, followed by soft-launches in France, Italy and Spain. The Company has been encouraged by the performance to date in these initial markets, with Eroxon taking >20% market share of approved ED treatments in the UK and Belgium within 12 months of launch. The success of the partnership to date was demonstrated through the recent extension of the licencing agreement with Cooper post the year end until January 2029, with full launches in at least ten countries including key European markets such as France, Italy and Spain remaining on track to take place before April 2024.'

I had two top ups today!

[takeiteasy] 09/2/2024 14:15

Just publicly available online government data on ED prescriptions sales that when looked at in terms of our information somewhat closely aligned to around 20% give or take a little - it is all out there in the public domain - my data was a year or two old - so you have to take some degree of approximation - but very much in the ball park. Without this reassurance I was feeling a little in the dark as they say...

[broomrigg] 09/2/2024 14:14

LOL thicko Glavey loves watching other people's shares go up. What a bellend.

[takeiteasy] 09/2/2024 10:32

That is interesting, we have all made some mistakes in our investing life times, I for one would slink into the shadows rather than keep up the public circus show that they do here - each to his own..

[broomrigg] 09/2/2024 10:29

Petroc is 100% correct with his summary of MDI/LBO etc.

[takeiteasy] 09/2/2024 10:12

their deramping game is up I agree...onwards and upwards...

[takeiteasy] 09/2/2024 09:58

you sound so sad as we break through 40p and your posting pales into insgnificance...can you find another share now to make your deramper postings on possibly where you have a better chance of making it :)

[mdi] 09/2/2024 09:56

And how can they claim a medical device which only has a CE mark would be capturing market share of oral PDE5I drugs which unlike Eroxon are proven to have effects beyond placebo in fully blinded placebo controlled studies. They are a separate category. And there are other ED medical devices on the market and maybe thats the 20% of the market they claiming to have captured? Also in European markets, medical devices don’t have to show any sort of improvement in symptoms; they just have to meet specific safety standards. In other words, the CE mark proves only that Eroxon is safe, not that it works.

[takeiteasy] 09/2/2024 09:39

It very roughly does stack up at 20% if you follow my assumption - but I would never suggest someone rely on it...simply the best I could find. So not misguiding at all.

I was initially very unsure about the 20% so did some digging to reassure myself.

I won't repeat my answer to the last point as you will end up as a carbon copy of MDI with press repeats all day and night :)

[glavey] 09/2/2024 09:32

"it has to be my assumption until someone at the firm confirms this is how they have done it"

The volume of 'pills' (Sildenafil, Tadalafil, Vardenafil et al.) must be known. You wrote that there is no other approved 'gel'. What else is there? Given that it is unlikely that the volume of 'pills' has fallen, one might "assume" the 20% is likely to be in addition.

They are claiming >20% of the ED market, not the recreational market.

Do you think that they might be misguiding?


"a bit like"
Coffee -> caffeine -> drug.

Eroxon -> placebo. How can anyone become dependent when there is no active ingredient?

[takeiteasy] 09/2/2024 09:09

a comment about as relevant as the price of a mars bar in 1960...lols...

[mdi] 09/2/2024 09:02

As was mentioned by others. The company once also said similar about their condom product market share after it launched. Which sadly now has gone on to have zero percent of the market.



CSD500 condom, has in its first month since launch rapidly achieved an estimated 15% share of the Netherlands online condom market by value.



Wellness Investors: Beware The Placebo Trap

Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones.

Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle.

[goldie40] 09/2/2024 09:01

on the way up loads on the bid

[takeiteasy] 09/2/2024 09:00

Dependent = they get used to it and it works, a bit like drinking a cup of decent cofee :)

[j777j] 09/2/2024 08:58

Next stop 60's

[takeiteasy] 09/2/2024 08:57

Because I am not the company and they present the RNS, I am working on the basis that if i were them that is what I would have chosen to calculate market share information - it has to be my assumption until someone at the firm confirms this is how they have done it. E.g. have they capture amazon sales or not?